We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab – was unable to improve on Opdivo alone in the RELATIVITY-098 ...

The decision to go all-in on the programme comes two years after BMS paid $80 million to take exclusive, worldwide opt-in rights to PRX005, and means that the big pharma will now be responsible ...

Create, view, edit, and share diagrams—either in Visio for the web or directly in Microsoft Teams—as part of your Microsoft 365 subscription. Simplify your system design process and illustrate how ...